AZD6793
Sponsors
AstraZeneca AB, AstraZeneca
Conditions
Chronic Obstructive Pulmonary Disease (COPD)Healthy ParticipantsInflammatory DiseasesModerate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)Type 2 Diabetes Mellitus
Phase 1
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics (PK) of Oral AZD6793 in Healthy and Chronic Obstructive Pulmonary Disease Participants, to Assess the Relative Oral Bioavailability Between Two Formulations, and the Food Effect on the PK of AZD6793 Compared to Fasting State.
CompletedNCT05662033
Start: 2022-12-05End: 2024-10-29Updated: 2025-10-29
A Study to Investigate the Safety and Pharmacokinetics of AZD6793 in Healthy Japanese and Chinese Participants
CompletedNCT06368440
Start: 2024-05-15End: 2024-12-23Updated: 2025-10-24
A Study to Assess the Pharmacokinetics of AZD6793 When Administered Alone and in Combination With Itraconazole in Healthy Participants.
CompletedNCT06494644
Start: 2024-07-23End: 2024-10-05Updated: 2025-05-31
A Study to Evaluate the Effect of AZD6793 on the Pharmacokinetics and Pharmacodynamics of Metformin in Participants With Type 2 Diabetes Mellitus
SuspendedNCT07433062
Start: 2026-01-14End: 2026-06-18Target: 28Updated: 2026-04-22
Phase 2
A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease
RecruitingNCT07082738
Start: 2025-06-27End: 2027-11-05Target: 987Updated: 2026-09-09
A Multicentre, Parallel-group, Phase IIb, Randomised, Double blind, Placebo-controlled, 4-Arm, 24-Week Study to Evaluate the Efficacy and Safety of AZD6793 Tablets in Adult Participants with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (PRESTO).
RecruitingCTIS2025-520473-40-00
Start: 2025-09-29Target: 314Updated: 2025-12-14